Researchers from Monash University have developed a new drug delivery strategy able to block pain within the nerve cells, in what could be a major development of an immediate and long lasting treatment for pain.
More than 100 million Americans suffer from chronic pain and this figure is expected to grow, driven by the increased life expectancy, increasing incidence of diabetes and cancer, combined with better survival rates, often leaving patients with severe and poorly treated pain. The global market for nerve pain treatments is over US$600 billion and yet current pain therapies are not completely effective and often suffer from unwanted side effects.
Research published in the journal, Science Translational Medicine, reveals how a target protein, long known to be associated with both chronic and acute pain, works within the nerve cell. This protein is the NK1 receptor, the receptor of the neuropeptide substance P, which mediates pain transmission. Because of its association with pain and other diseases of the nervous system, many drug development attempts have focused on inhibiting this receptor, but the efficacy of these treatments has been very limited. This new work shows that such ineffectiveness could be in part because the treatments targeted the protein on the surface of the nerve cell.
Dr Michelle Halls and Dr Meritxell Canals from the Monash Institute of Pharmaceutical Sciences (MIPS) and the ARC Centre for Excellence in Bio-Nano Science (CBNS) at Monash University, have worked with Professor Nigel Bunnett, previously at Monash and now at Columbia University in the US, and Professor Chris Porter from MIPS and CBNS.
Together they have found that the NK-1 receptor controls pain once it is inside the cell — so drugs that merely block it when it is on the surface of the cell have little efficacy. Instead, this new research shows that, in animal models, if the NK-1 receptor is blocked once it enters the nerve cell, it is possible to suppress pain more effectively.
Dr Halls said that the new strategy of “targeting receptors inside the cell represents a new frontier in drug delivery and a novel therapeutic strategy for dealing with pain.”
Working with a multidisciplinary team of cell biologists, pharmacologists, physiologists and drug delivery experts, the researchers developed drugs that specifically target NK-1 receptors within the nerve cell. Animal studies showed that using the drugs — which have an engineered lipid attachment that targets the drug to the NK-1 receptor inside the cell, could block pain for extended periods in several animal models.
Dr Canals said: “This is a proof-of-concept study that shows that we can re-engineer current pain drugs and make them more effective. The challenge is now to translate the technology into human clinical trials. This is a complex and challenging path — but the ultimate benefits to patients with nerve pain are potentially highly significant.”
[osd_subscribe categories=’pain’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “PAIN’]
The Latest on: Pain relief
- Team of WFU doctors gets $9M grant to study 'love hormore' as pain treatment
Scientists at Wake Forest University School of Medicine have been awarded approximately $9 million to study the use of oxytocin, sometimes called the "love hormone," as a pain treatment.
- Medical Marijuana May Offer Safe Pain Relief for Cancer Patients
Pain, depression, anxiety and insomnia all affect patients undergoing cancer treatment and can lead to a poor prognosis, doctors say. "Traditionally, cancer-related pain is mainly treated by ...
- If You Experience Lower-Back Pain From Sitting, Here Are 8 Ways to Find Relief
If you work a job that requires sitting at a desk (either at home or in an office) for the majority of the day, then you know the never-ending battle of lower back pain. All it takes is a few days of ...
- Pain Relief Medication Market boosted by rising demand for digitization in organizations with key player
An exceptional Pain Relief Medication market report takes into consideration diverse segments of the market analysis that today’s business ask for. The report provides estimations of CAGR values ...
- Topical Pain Relief Market Huge Growth Opportunities, Emerging Trends, Revenue Analysis Opportunity, Outlook, And Demand Forecast To 2028
Research Nester has released a reporttitled “ Topical Pain Relief Market – Global Demand Analysis & Opportunity Outlook 2028” which also includes some of the prominent market analyzing ...
via Google News and Bing News